Skip Navigation



Annals of Oncology Advance Access published online on June 20, 2006
Annals of Oncology, doi:10.1093/annonc/mdl136
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/9/1393    most recent
mdl136v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Semple, S. I. K.
Right arrow Articles by Gilbert, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semple, S. I. K.
Right arrow Articles by Gilbert, F. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received January 17, 2006
Revised March 30, 2006
Accepted May 5, 2006

original article

Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration

S. I. K. Semple 1 *, R. T. Staff 2, S. D. Heys 3, T. W. Redpath 1, A. E. Welch 4, T. S. Ahearn 1, A. W. Hutcheon 5, and F. J. Gilbert 1

1 Department of Radiology, University of Aberdeen, Scotland, UK
2 Department of Nuclear Medicine, Grampian University Hospitals NHS Trust, Foresterhill, Aberdeen, Scotland, UK
3 Department of Surgery, University of Aberdeen, Scotland, UK
4 Department of School of Medical Sciences, University of Aberdeen, Scotland, UK
5 Department of Clinical Oncology, Aberdeen Royal Infirmary, Grampian University Hospitals NHS Trust, Foresterhill, Aberdeen, Scotland, UK

* To whom correspondence should be addressed.
S. I. K. Semple, E-mail: s.semple{at}abdn.ac.uk


  Abstract

Background: The aim of the study was to investigate whether pre-therapy vascular delivery assessment [using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)] can predict reduction in breast cancer metabolism [detected using 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET)] after a single cycle of chemotherapy. Reduction in 18F-FDG PET metabolism has previously been shown to correlate with histological response to primary chemotherapy.

Patients and methods: Seventeen patients with large or locally advanced invasive ductal carcinomas of the breast were imaged using DCE-MRI and 18F-FDG-PET prior to therapy and 20 days after the first cycle of chemotherapy. MRI data were analysed using a multi-compartment model. PET data were analysed using standardised uptake value (SUV) analysis.

Results: A significant association (P <0.05) was observed between pre-therapy DCE-MRI vascular parameters and the reduction in PET metabolism resulting from administration of one cycle of chemotherapy.

Conclusions: A relationship was demonstrated between pre-therapy DCE-MRI vascular parameters and the reduction in PET metabolism after a single cycle of chemotherapy. This suggests that reduction in PET metabolism as a result of chemotherapy may be dependent, at least in part, on pre-therapy vascular delivery. These pre-therapy vascular characteristics may be suitable for use as a surrogate measure for initial chemotherapy delivery, a key factor in chemotherapeutic efficacy.

Keywords: breast cancer; dynamic MRI; 18F-FDG PET; chemotherapy; efficacy; delivery.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.